Compare Gilead Sciences, Inc. (GILD) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Clear Secure Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Gilead Sciences, Inc. is far larger — about 41.1× Clear Secure Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Clear Secure Inc for 19 Days on average.
| GILD | YOU | |
|---|---|---|
Market Cap | $182.40B | $4.44B |
Volume | 4,469,821 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $155.80 | $62.36 |
52-Week Low | $116.74 | $29.61 |
Typical Hold Time | 111 Days | 19 Days |
Enterprise Value | $205.46B | $3.59B |
Dividend Yield | 2.23% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Clear Secure (YOU) trades at $43.43, up 2.0% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Analyst consensus is mixed with a $61.40 price target, and the stock shows robust profitability with a 90.29% ROE and expanding margins.
The outlook is positive given membership growth and new enterprise initiatives, but risks include high valuation multiples and insider selling. The stock offers growth potential driven by identity platform expansion, though investors should weigh competitive pressures and execution risks against strong fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
